|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein] |
CTD |
PMID:29883672 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] |
CTD |
PMID:29883672 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein] |
CTD |
PMID:29883672 |
|
NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein] |
CTD |
PMID:29883672 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CD28 |
CD28 molecule |
multiple interactions |
EXP |
2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:14607919 |
|
NCBI chr 2:203,706,482...203,738,912
Ensembl chr 2:203,706,517...203,739,756
|
|
G |
GRM1 |
glutamate metabotropic receptor 1 |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] |
CTD |
PMID:14622174 |
|
NCBI chr 6:146,027,707...146,437,601
Ensembl chr 6:146,027,646...146,437,601
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
2-aminoethoxydiphenylborane inhibits the reaction [bisphenol A results in increased expression of NFE2L2 protein] |
CTD |
PMID:33408296 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
|
G |
ADRA1B |
adrenoceptor alpha 1B |
multiple interactions |
ISO |
4-Aminopyridine inhibits the reaction [ADRA1B protein results in increased susceptibility to Phenylephrine] |
CTD |
PMID:18480251 |
|
NCBI chr 5:159,865,086...159,989,205
Ensembl chr 5:159,865,080...159,973,012
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
4-Aminopyridine results in increased expression of BAX mRNA |
CTD |
PMID:24378259 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BIRC2 |
baculoviral IAP repeat containing 2 |
decreases expression |
ISO |
4-Aminopyridine results in decreased expression of BIRC2 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
|
|
G |
BIRC3 |
baculoviral IAP repeat containing 3 |
decreases expression |
ISO |
4-Aminopyridine results in decreased expression of BIRC3 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403
|
|
G |
BMF |
Bcl2 modifying factor |
increases expression |
ISO |
4-Aminopyridine results in increased expression of BMF mRNA |
CTD |
PMID:24378259 |
|
NCBI chr15:40,087,890...40,108,879
Ensembl chr15:40,087,890...40,108,892
|
|
G |
C1orf159 |
chromosome 1 open reading frame 159 |
increases expression |
ISO |
4-Aminopyridine results in increased expression of C1ORF159 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 1:1,081,823...1,116,089
Ensembl chr 1:1,081,818...1,116,361
|
|
G |
CASP3 |
caspase 3 |
increases activity |
ISO |
4-Aminopyridine results in increased activity of CASP3 protein |
CTD |
PMID:24378259 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
increases activity |
ISO |
4-Aminopyridine results in increased activity of CASP7 protein |
CTD |
PMID:24378259 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP9 |
caspase 9 |
increases activity |
ISO |
4-Aminopyridine results in increased activity of CASP9 protein |
CTD |
PMID:24378259 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CD40 |
CD40 molecule |
increases expression |
ISO |
4-Aminopyridine results in increased expression of CD40 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863
|
|
G |
CD40LG |
CD40 ligand |
increases expression |
ISO |
4-Aminopyridine results in increased expression of CD40LG mRNA |
CTD |
PMID:24378259 |
|
NCBI chr X:136,648,158...136,660,390
Ensembl chr X:136,648,158...136,660,390
|
|
G |
CTSB |
cathepsin B |
increases expression |
ISO |
4-Aminopyridine results in increased expression of CTSB mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533
|
|
G |
DPYSL4 |
dihydropyrimidinase like 4 |
increases expression |
ISO |
4-Aminopyridine results in increased expression of DPYSL4 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr10:132,186,948...132,205,759
Ensembl chr10:132,186,948...132,205,759
|
|
G |
GAD2 |
glutamate decarboxylase 2 |
increases expression multiple interactions |
ISO |
4-Aminopyridine results in increased expression of GAD2 mRNA KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA] |
CTD |
PMID:25917026 |
|
NCBI chr10:26,216,372...26,304,558
Ensembl chr10:26,216,665...26,304,558
|
|
G |
GALNT5 |
polypeptide N-acetylgalactosaminyltransferase 5 |
decreases expression |
ISO |
4-Aminopyridine results in decreased expression of GALNT5 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 2:157,257,705...157,318,491
Ensembl chr 2:157,257,705...157,318,491
|
|
G |
GRIN2D |
glutamate ionotropic receptor NMDA type subunit 2D |
multiple interactions |
ISO |
[Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein |
CTD |
PMID:19911010 |
|
NCBI chr19:48,393,668...48,444,931
Ensembl chr19:48,393,668...48,444,931
|
|
G |
HDAC5 |
histone deacetylase 5 |
multiple interactions |
ISO |
[Bicuculline co-treated with 4-Aminopyridine] affects the localization of HDAC5 protein |
CTD |
PMID:15773917 |
|
NCBI chr17:44,076,753...44,123,641
Ensembl chr17:44,076,746...44,123,702
|
|
G |
JPH3 |
junctophilin 3 |
increases expression |
ISO |
4-Aminopyridine results in increased expression of JPH3 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr16:87,601,835...87,698,156
Ensembl chr16:87,601,835...87,698,156
|
|
G |
KCNA10 |
potassium voltage-gated channel subfamily A member 10 |
multiple interactions |
EXP |
4-Aminopyridine inhibits the reaction [KCNA10 protein results in increased transport of Potassium] |
CTD |
PMID:10836990 |
|
NCBI chr 1:110,517,217...110,519,175
Ensembl chr 1:110,517,217...110,519,175
|
|
G |
KCND3 |
potassium voltage-gated channel subfamily D member 3 |
increases expression multiple interactions |
ISO |
4-Aminopyridine results in increased expression of KCND3 mRNA KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA] |
CTD |
PMID:25917026 |
|
NCBI chr 1:111,770,662...111,989,668
Ensembl chr 1:111,770,662...111,989,668
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
4-Aminopyridine results in decreased activity of KCNH2 protein |
CTD |
PMID:19915712 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KCNIP1 |
potassium voltage-gated channel interacting protein 1 |
decreases expression increases expression multiple interactions |
ISO |
4-Aminopyridine results in decreased expression of KCNIP1 mRNA 4-Aminopyridine results in increased expression of KCNIP1 mRNA KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased abundance of gamma-Aminobutyric Acid]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA] |
CTD |
PMID:24378259 PMID:25917026 |
|
NCBI chr 5:170,353,487...170,736,632
Ensembl chr 5:170,353,487...170,736,632
|
|
G |
KCNN4 |
potassium calcium-activated channel subfamily N member 4 |
decreases expression |
EXP |
4-aminopyridine decreases expression of KCNN4 mRNA and protein in CD4-positive alpha-beta T cell |
RGD |
PMID:26502942 |
RGD:329955577 |
NCBI chr19:43,766,533...43,780,973
Ensembl chr19:43,766,533...43,780,976
|
|
G |
MAG |
myelin associated glycoprotein |
decreases expression |
ISO |
4-Aminopyridine results in decreased expression of MAG mRNA |
CTD |
PMID:24378259 |
|
NCBI chr19:35,292,161...35,313,807
Ensembl chr19:35,292,125...35,313,807
|
|
G |
MAP1LC3A |
microtubule associated protein 1 light chain 3 alpha |
increases expression |
ISO |
4-Aminopyridine results in increased expression of MAP1LC3A mRNA |
CTD |
PMID:24378259 |
|
NCBI chr20:34,546,844...34,560,345
Ensembl chr20:34,546,854...34,560,345
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein] 4-Aminopyridine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19911010 PMID:22759588 PMID:28132918 PMID:33621091 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein] 4-Aminopyridine results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19911010 PMID:22759588 PMID:28132918 PMID:33621091 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
NCOR2 |
nuclear receptor corepressor 2 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein] |
CTD |
PMID:15773917 |
|
NCBI chr12:124,324,415...124,567,612
Ensembl chr12:124,324,415...124,567,612
|
|
G |
PRKACA |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions increases phosphorylation |
ISO |
lappaconitine inhibits the reaction [4-Aminopyridine results in increased phosphorylation of PRKACA protein] |
CTD |
PMID:35643327 |
|
NCBI chr19:14,091,688...14,117,762
Ensembl chr19:14,091,688...14,118,084
|
|
G |
RARA |
retinoic acid receptor alpha |
multiple interactions |
ISO |
[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]] |
CTD |
PMID:15773917 |
|
NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643
|
|
G |
S100A7A |
S100 calcium binding protein A7A |
decreases expression |
ISO |
4-Aminopyridine results in decreased expression of S100A7A mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 1:153,416,520...153,423,222
Ensembl chr 1:153,416,520...153,423,222
|
|
G |
SNAP25 |
synaptosome associated protein 25 |
increases phosphorylation multiple interactions |
ISO |
4-Aminopyridine results in increased phosphorylation of SNAP25 protein lappaconitine inhibits the reaction [4-Aminopyridine results in increased phosphorylation of SNAP25 protein] |
CTD |
PMID:35643327 |
|
NCBI chr20:10,218,830...10,307,418
Ensembl chr20:10,172,395...10,308,258
|
|
G |
SYN1 |
synapsin I |
affects response to substance multiple interactions increases response to substance increases expression |
ISO |
SYN1 protein affects the susceptibility to 4-Aminopyridine [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein; ciproxifan inhibits the reaction [4-Aminopyridine results in increased expression of SYN1 protein modified form]; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein] SYN1 results in increased susceptibility to 4-Aminopyridine |
CTD |
PMID:22759588 PMID:28132918 PMID:33621091 |
|
NCBI chr X:47,571,901...47,619,857
Ensembl chr X:47,571,901...47,619,857
|
|
G |
TRAF2 |
TNF receptor associated factor 2 |
increases expression |
ISO |
4-Aminopyridine results in increased expression of TRAF2 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 9:136,881,958...136,926,607
Ensembl chr 9:136,881,912...136,926,607
|
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
multiple interactions |
ISO |
[barium chloride results in increased abundance of Barium] which results in decreased activity of ACHE protein |
CTD |
PMID:31407482 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ALB |
albumin |
multiple interactions increases secretion |
ISO |
Plant Extracts inhibits the reaction [barium chloride results in increased secretion of ALB protein] |
CTD |
PMID:26732703 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
CAT |
catalase |
multiple interactions decreases activity |
ISO |
[[Sodium Selenite results in increased abundance of Selenium] which co-treated with Ascorbic Acid] inhibits the reaction [barium chloride results in decreased activity of CAT protein]; [barium chloride results in increased abundance of Barium] which results in decreased activity of CAT protein; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [barium chloride results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [barium chloride results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [barium chloride results in decreased activity of CAT protein] |
CTD |
PMID:26732703 PMID:27941167 PMID:28683652 PMID:31407482 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
barium chloride inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; barium chloride inhibits the reaction [TNF protein results in increased expression of F3 protein] |
CTD |
PMID:23305835 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
GGT1 |
gamma-glutamyltransferase 1 |
increases activity |
ISO |
barium chloride results in increased activity of GGT1 protein |
CTD |
PMID:28683652 |
|
NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005
|
|
G |
GOT1 |
glutamic-oxaloacetic transaminase 1 |
increases activity |
ISO |
barium chloride results in increased activity of GOT1 protein |
CTD |
PMID:28683652 |
|
NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624
|
|
G |
GPT |
glutamic--pyruvic transaminase |
increases activity |
ISO |
barium chloride results in increased activity of GPT protein |
CTD |
PMID:28683652 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases activity |
ISO |
barium chloride results in decreased activity of GPX1 protein |
CTD |
PMID:28683652 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
IL1B |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
barium chloride results in increased expression of IL1B mRNA Plant Extracts inhibits the reaction [barium chloride results in increased expression of IL1B mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
barium chloride results in increased expression of IL6 mRNA [barium chloride results in increased abundance of Barium] which results in increased expression of IL6 protein; Plant Extracts inhibits the reaction [barium chloride results in increased expression of IL6 mRNA] |
CTD |
PMID:26732703 PMID:31407482 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
KCNE1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
EXP |
barium chloride results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr21:34,446,688...34,512,210
Ensembl chr21:34,446,688...34,512,214
|
|
G |
KCNJ2 |
potassium inwardly rectifying channel subfamily J member 2 |
multiple interactions |
ISO |
barium chloride inhibits the reaction [KCNJ2 protein results in increased transport of Potassium] |
CTD |
PMID:11087224 |
|
NCBI chr17:70,169,532...70,180,044
Ensembl chr17:70,168,673...70,180,044
|
|
G |
KCNK3 |
potassium two pore domain channel subfamily K member 3 |
decreases activity |
ISO |
barium chloride results in decreased activity of KCNK3 protein |
CTD |
PMID:16020457 |
|
NCBI chr 2:26,692,722...26,733,420
Ensembl chr 2:26,692,722...26,733,420
|
|
G |
KCNQ1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions |
EXP |
barium chloride results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr11:2,445,008...2,849,105
Ensembl chr11:2,444,654...2,849,105
|
|
G |
LDHA |
lactate dehydrogenase A |
increases activity |
ISO |
barium chloride results in increased activity of LDHA protein |
CTD |
PMID:28683652 |
|
NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425
|
|
G |
MT1A |
metallothionein 1A |
multiple interactions increases expression |
ISO |
Plant Extracts inhibits the reaction [barium chloride results in increased expression of MT1 mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr16:56,638,666...56,640,087
Ensembl chr16:56,638,666...56,640,087
|
|
G |
MT2A |
metallothionein 2A |
increases expression multiple interactions |
ISO |
barium chloride results in increased expression of MT2A mRNA Plant Extracts inhibits the reaction [barium chloride results in increased expression of MT2A mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
SERPINE1 |
serpin family E member 1 |
increases secretion |
ISO |
barium chloride results in increased secretion of SERPINE1 protein |
CTD |
PMID:21596853 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
ISO |
barium chloride results in decreased expression of SOD2 mRNA Plant Extracts inhibits the reaction [barium chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
STX1A |
syntaxin 1A |
multiple interactions affects localization |
ISO |
Propofol inhibits the reaction [barium chloride affects the localization of STX1A protein]; STX1A protein modified form inhibits the reaction [Propofol inhibits the reaction [barium chloride affects the localization of STX1A protein]] |
CTD |
PMID:29320738 |
|
NCBI chr 7:73,699,210...73,719,669
Ensembl chr 7:73,699,206...73,719,672
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
Plant Extracts inhibits the reaction [barium chloride results in increased expression of TNF mRNA] barium chloride inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; barium chloride inhibits the reaction [TNF protein results in increased expression of F3 protein] |
CTD |
PMID:23305835 PMID:26732703 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TSC22D3 |
TSC22 domain family member 3 |
multiple interactions |
ISO |
[barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA] |
CTD |
PMID:29957541 |
|
NCBI chr X:107,713,221...107,775,988
Ensembl chr X:107,713,221...107,777,342
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
increases expression |
EXP |
berberine increases expression of abca1 protein in mouse liver and human hepatocytes |
RGD |
PMID:29505790 |
RGD:19165131 |
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases expression |
ISO |
Berberine results in increased expression of ABCB1A mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ACADM |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575
|
|
G |
ACAN |
aggrecan |
decreases expression |
EXP |
Berberine results in decreased expression of ACAN mRNA |
CTD |
PMID:26478571 |
|
NCBI chr15:88,803,436...88,875,353
Ensembl chr15:88,803,436...88,875,353
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
multiple interactions decreases activity |
ISO EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Berberine inhibits the reaction [acetamiprid results in increased activity of ACHE protein] Berberine results in decreased activity of ACHE protein |
CTD |
PMID:29170048 PMID:33844597 PMID:37350525 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of ACTA2 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA] |
CTD |
PMID:17973934 PMID:37839514 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
AGER |
advanced glycosylation end-product specific receptor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 6:32,180,969...32,184,253
Ensembl chr 6:32,180,968...32,184,322
|
|
G |
AHR |
aryl hydrocarbon receptor |
increases activity |
ISO EXP |
Berberine results in increased activity of AHR protein |
CTD |
PMID:16046213 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP ISO |
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23954465 PMID:30138605 PMID:33325633 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr19:40,230,317...40,285,345
Ensembl chr19:40,230,317...40,285,536
|
|
G |
ALB |
albumin |
multiple interactions |
ISO |
Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] |
CTD |
PMID:30138605 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
AURKB |
aurora kinase B |
decreases expression |
EXP |
Berberine results in decreased expression of AURKB mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:8,204,731...8,210,575
Ensembl chr17:8,204,733...8,210,600
|
|
G |
AURKC |
aurora kinase C |
increases expression |
EXP |
Berberine results in increased expression of AURKC mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:57,231,023...57,235,548
Ensembl chr19:57,231,009...57,235,548
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of BAX mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:35439518 PMID:36070022 More...
|
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BBC3 |
BCL2 binding component 3 |
increases expression multiple interactions |
EXP |
Berberine results in increased expression of BBC3 mRNA [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression increases expression multiple interactions |
EXP ISO |
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 PMID:26712469 PMID:30138605 PMID:35439518 PMID:36070022 More...
|
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
Berberine results in decreased expression of BCL2L1 protein |
CTD |
PMID:16505103 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BCL2L11 |
BCL2 like 11 |
multiple interactions increases expression |
EXP |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA Berberine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BECN1 mRNA] Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein] |
CTD |
PMID:35439518 PMID:38705399 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions |
EXP |
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein] |
CTD |
PMID:26478571 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
affects binding |
EXP |
Berberine binds to BIRC5 promoter |
CTD |
PMID:17968851 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
multiple interactions increases expression |
EXP ISO |
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3 protein Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein] Berberine results in increased expression of BNIP3 protein |
CTD |
PMID:36070022 PMID:38705399 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
BNIP3L |
BCL2 interacting protein 3 like |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine results in increased expression of BNIP3L protein |
CTD |
PMID:36070022 |
|
NCBI chr 8:26,383,054...26,413,127
Ensembl chr 8:26,383,054...26,505,636
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA] |
CTD |
PMID:38705399 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
EXP ISO |
[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP3 protein] Berberine increases activity of CASP3 protein in colon epithelial cells Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of CASP3 mRNA] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA |
CTD RGD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:33460233 PMID:35439518 PMID:36070022 PMID:37839514 PMID:29564000 More...
|
RGD:152995489 |
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
increases activity |
EXP |
Berberine results in increased activity of CASP8 protein |
CTD |
PMID:20656010 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
increases cleavage multiple interactions |
EXP ISO |
Berberine results in increased cleavage of CASP9 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP9 protein] [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein |
CTD |
PMID:16505103 PMID:26712469 PMID:30138605 PMID:37839514 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [acetamiprid results in decreased activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of CAT protein] |
CTD |
PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 PMID:33460233 PMID:35121005 PMID:35439518 PMID:35691465 PMID:37350525 PMID:37839514 More...
|
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA] |
CTD |
PMID:16391493 PMID:35691465 PMID:38705399 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCND1 |
cyclin D1 |
decreases expression multiple interactions |
EXP |
Berberine results in decreased expression of CCND1 protein Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA] |
CTD |
PMID:16505103 PMID:33325633 PMID:36822301 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND2 |
cyclin D2 |
decreases expression |
EXP |
Berberine results in decreased expression of CCND2 protein |
CTD |
PMID:16505103 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CCNE1 |
cyclin E1 |
decreases expression |
EXP |
Berberine results in decreased expression of CCNE1 protein |
CTD |
PMID:16505103 |
|
NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
|
|
G |
CCNT1 |
cyclin T1 |
multiple interactions |
ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein] |
CTD |
PMID:20828602 |
|
NCBI chr12:48,688,458...48,716,707
Ensembl chr12:48,688,458...48,716,998
|
|
G |
CD36 |
CD36 molecule (CD36 blood group) |
multiple interactions increases expression |
EXP ISO |
15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein |
CTD |
PMID:28038998 PMID:29408570 |
|
NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Particulate Matter results in decreased expression of CDH1 mRNA] |
CTD |
PMID:37839514 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH2 |
cadherin 2 |
decreases expression |
EXP |
Berberine results in decreased expression of CDH2 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
decreases expression |
EXP |
Berberine results in decreased expression of CDK2 protein |
CTD |
PMID:16505103 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
decreases expression multiple interactions |
EXP |
Berberine results in decreased expression of CDK4 protein Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA] |
CTD |
PMID:16505103 PMID:36822301 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDK6 |
cyclin dependent kinase 6 |
decreases expression |
EXP |
Berberine results in decreased expression of CDK6 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573
|
|
G |
CDK9 |
cyclin dependent kinase 9 |
multiple interactions |
ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 9:127,786,034...127,790,792
Ensembl chr 9:127,785,679...127,790,792
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
Berberine results in increased expression of CDKN1A protein |
CTD |
PMID:16505103 PMID:23747414 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression |
EXP |
Berberine results in increased expression of CDKN1B protein |
CTD |
PMID:16505103 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CDKN1C |
cyclin dependent kinase inhibitor 1C |
increases expression |
EXP |
Berberine results in increased expression of CDKN1C mRNA |
CTD |
PMID:26478571 |
|
NCBI chr11:2,883,218...2,885,775
Ensembl chr11:2,883,213...2,885,775
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions decreases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA; Berberine results in decreased expression of CEBPA protein |
CTD |
PMID:20564506 PMID:26478571 PMID:37511356 |
|
NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534
|
|
G |
CEBPB |
CCAAT enhancer binding protein beta |
increases expression affects phosphorylation multiple interactions |
EXP ISO |
Berberine results in increased expression of CEBPB mRNA Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] |
CTD |
PMID:28038998 |
|
NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,734...50,192,690
|
|
G |
CHEK1 |
checkpoint kinase 1 |
increases expression |
EXP |
Berberine results in increased expression of CHEK1 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255
|
|
G |
CHEK2 |
checkpoint kinase 2 |
increases expression |
EXP |
Berberine results in increased expression of CHEK2 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422
|
|
G |
COL10A1 |
collagen type X alpha 1 chain |
increases expression |
EXP |
Berberine results in increased expression of COL10A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 6:116,118,909...116,217,144
Ensembl chr 6:116,118,909...116,158,747
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
EXP ISO |
Berberine results in increased expression of COL1A1 mRNA Berberine inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26478571 PMID:37839514 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
decreases expression |
EXP |
Berberine results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
COL3A1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Particulate Matter results in increased expression of COL3A1 mRNA] |
CTD |
PMID:37839514 |
|
NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746
|
|
G |
COX4I1 |
cytochrome c oxidase subunit 4I1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of COX4I1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr16:85,799,695...85,807,068
Ensembl chr16:85,798,633...85,807,068
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] |
CTD |
PMID:35121005 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CREBBP |
CREB binding protein |
increases expression |
EXP |
Berberine results in increased expression of CREBBP mRNA |
CTD |
PMID:27311644 |
|
NCBI chr16:3,725,054...3,880,713
Ensembl chr16:3,725,054...3,880,713
|
|
G |
CST3 |
cystatin C |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein] |
CTD |
PMID:38705399 |
|
NCBI chr20:23,626,706...23,637,955
Ensembl chr20:23,626,706...23,638,473
|
|
G |
CTNNB1 |
catenin beta 1 |
increases expression multiple interactions |
EXP |
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CTSD |
cathepsin D |
multiple interactions decreases cleavage |
EXP |
GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSD protein] |
CTD |
PMID:36070022 |
|
NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573
|
|
G |
CTSL |
cathepsin L |
multiple interactions decreases cleavage |
EXP |
Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein] |
CTD |
PMID:36070022 |
|
NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of CXCL8 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:16391493 PMID:28916288 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization multiple interactions |
EXP |
Berberine affects the localization of CYCS protein [Berberine co-treated with Cisplatin] results in increased expression of CYCS protein |
CTD |
PMID:16505103 PMID:36070022 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity increases expression multiple interactions |
EXP ISO |
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16046213 PMID:22342832 PMID:24583342 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] Berberine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:22342832 PMID:25455889 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions decreases expression decreases activity |
EXP ISO |
[Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] |
CTD |
PMID:21524698 PMID:30086269 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DKK1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
EXP |
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
decreases expression |
EXP |
Berberine results in decreased expression of DNMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286
|
|
G |
DNMT3B |
DNA methyltransferase 3 beta |
decreases expression |
EXP |
Berberine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:32,762,385...32,809,356
Ensembl chr20:32,762,385...32,809,359
|
|
G |
DZIP3 |
DAZ interacting zinc finger protein 3 |
increases expression |
EXP |
Berberine results in increased expression of DZIP3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:108,589,510...108,694,840
Ensembl chr 3:108,589,705...108,694,840
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
decreases expression |
EXP |
Berberine results in decreased expression of EGFR protein |
CTD |
PMID:33325633 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
|
|
G |
EP300 |
E1A binding protein p300 |
increases expression |
EXP |
Berberine results in increased expression of EP300 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,510...41,180,077
|
|
G |
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein |
CTD |
PMID:33325633 |
|
NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESRRA |
estrogen related receptor alpha |
multiple interactions |
EXP |
Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr11:64,305,524...64,316,743
Ensembl chr11:64,305,497...64,316,743
|
|
G |
FABP4 |
fatty acid binding protein 4 |
decreases expression increases expression multiple interactions |
EXP ISO |
Berberine results in decreased expression of FABP4 mRNA Berberine results in increased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA] |
CTD |
PMID:26478571 PMID:29408570 |
|
NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236
|
|
G |
FAS |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO EXP |
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein |
CTD |
PMID:20564506 PMID:20656010 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FASLG |
Fas ligand |
increases expression |
EXP |
Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein |
CTD |
PMID:20656010 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FN1 |
fibronectin 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of FN1 mRNA] |
CTD |
PMID:30138605 PMID:37839514 |
|
NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073
|
|
G |
FOXO1 |
forkhead box O1 |
multiple interactions |
EXP |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:26712469 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FOXO3 |
forkhead box O3 |
multiple interactions |
EXP |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:26712469 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
FUNDC1 |
FUN14 domain containing 1 |
increases expression multiple interactions |
EXP |
Berberine results in increased expression of FUNDC1 protein [Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:44,523,639...44,542,859
Ensembl chr X:44,523,639...44,542,859
|
|
G |
GATA2 |
GATA binding protein 2 |
increases expression |
ISO |
Berberine results in increased expression of GATA2 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr 3:128,479,422...128,493,201
Ensembl chr 3:128,479,427...128,493,201
|
|
G |
GATA3 |
GATA binding protein 3 |
increases expression |
ISO |
Berberine results in increased expression of GATA3 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr10:8,045,333...8,075,198
Ensembl chr10:8,045,378...8,075,198
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
|
|
G |
GDF5 |
growth differentiation factor 5 |
decreases expression |
EXP |
Berberine results in decreased expression of GDF5 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr20:35,433,347...35,454,749
Ensembl chr20:35,433,347...35,454,746
|
|
G |
GFAP |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] |
CTD |
PMID:24751971 PMID:25455889 PMID:30138605 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA] |
CTD |
PMID:24751971 PMID:33460233 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO EXP |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:20462044 PMID:23954465 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of GSR protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:24751971 PMID:25600690 PMID:33460233 PMID:35439518 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
H2AC11 |
H2A clustered histone 11 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,133,043...27,133,535
Ensembl chr 6:27,133,043...27,135,292
|
|
G |
H2AC12 |
H2A clustered histone 12 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,147,106...27,147,562
Ensembl chr 6:27,147,106...27,147,562
|
|
G |
H2AC14 |
H2A clustered histone 14 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC14 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,814,302...27,814,777
Ensembl chr 6:27,814,302...27,814,777
|
|
G |
H2AC15 |
H2A clustered histone 15 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC15 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,837,880...27,838,375
Ensembl chr 6:27,835,508...27,838,375
|
|
G |
H2AC17 |
H2A clustered histone 17 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC17 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,892,699...27,893,185
Ensembl chr 6:27,892,699...27,893,185
|
|
G |
H2AC18 |
H2A clustered histone 18 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC18 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:149,842,218...149,842,750
Ensembl chr 1:149,842,218...149,842,750
|
|
G |
H2AC25 |
H2A clustered histone 25 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC25 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:228,457,364...228,457,873
Ensembl chr 1:228,434,777...228,457,873
|
|
G |
H2AC4 |
H2A clustered histone 4 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,033,092...26,033,618
Ensembl chr 6:26,033,092...26,033,618
|
|
G |
H2AC6 |
H2A clustered histone 6 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,124,172...26,124,690
Ensembl chr 6:26,124,145...26,139,116
|
|
G |
H2AC8 |
H2A clustered histone 8 |
decreases expression |
EXP |
Berberine results in decreased expression of H2AC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,216,921...26,217,437
Ensembl chr 6:26,216,921...26,218,515
|
|
G |
H2AX |
H2A.X variant histone |
increases expression decreases expression multiple interactions |
EXP |
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] |
CTD |
PMID:23363784 PMID:23747414 PMID:27311644 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
H2BC11 |
H2B clustered histone 11 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,132,316...27,132,795
Ensembl chr 6:27,122,657...27,132,795
|
|
G |
H2BC12 |
H2B clustered histone 12 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,138,293...27,146,858
Ensembl chr 6:27,137,298...27,146,855
|
|
G |
H2BC13 |
H2B clustered histone 13 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC13 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,807,479...27,807,929
Ensembl chr 6:27,807,479...27,807,929
|
|
G |
H2BC14 |
H2B clustered histone 14 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC14 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,815,022...27,815,489
Ensembl chr 6:27,815,022...27,815,489
|
|
G |
H2BC15 |
H2B clustered histone 15 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC15 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,838,569...27,839,110
Ensembl chr 6:27,838,545...27,855,709
|
|
G |
H2BC17 |
H2B clustered histone 17 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC17 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,893,425...27,893,891
Ensembl chr 6:27,893,425...27,893,891
|
|
G |
H2BC4 |
H2B clustered histone 4 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,113,170...26,123,926
Ensembl chr 6:26,086,317...26,123,926
|
|
G |
H2BC5 |
H2B clustered histone 5 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,158,121...26,171,349
Ensembl chr 6:26,158,122...26,171,349
|
|
G |
H2BC6 |
H2B clustered histone 6 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,183,761...26,184,230
Ensembl chr 6:26,172,059...26,184,655
|
|
G |
H2BC7 |
H2B clustered histone 7 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,199,516...26,199,988
Ensembl chr 6:26,199,516...26,199,988
|
|
G |
H2BC8 |
H2B clustered histone 8 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,216,200...26,216,688
Ensembl chr 6:26,216,200...26,216,688
|
|
G |
H2BC9 |
H2B clustered histone 9 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,251,614...26,252,075
Ensembl chr 6:26,251,614...26,252,075
|
|
G |
H2BW2 |
H2B.W histone 2 |
decreases expression |
EXP |
Berberine results in decreased expression of H2BW2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:104,039,956...104,042,454
Ensembl chr X:104,039,956...104,042,454
|
|
G |
H3-3A |
H3.3 histone A |
decreases expression |
EXP |
Berberine results in decreased expression of H3-3A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:226,061,831...226,072,019
Ensembl chr 1:226,061,851...226,072,019
|
|
G |
H3-4 |
H3.4 histone, cluster member |
decreases expression |
EXP |
Berberine results in decreased expression of H3-4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:228,424,845...228,425,360
Ensembl chr 1:228,424,845...228,425,360
|
|
G |
H3C1 |
H3 clustered histone 1 |
decreases expression |
EXP |
Berberine results in decreased expression of H3C1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,020,451...26,020,958
Ensembl chr 6:26,020,451...26,020,958
|
|
G |
H3C10 |
H3 clustered histone 10 |
decreases expression |
EXP |
Berberine results in decreased expression of H3C10 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,810,051...27,810,536
Ensembl chr 6:27,810,051...27,811,300
|
|
G |
H3C12 |
H3 clustered histone 12 |
decreases expression |
EXP |
Berberine results in decreased expression of H3C12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,890,315...27,890,826
Ensembl chr 6:27,890,315...27,893,106
|
|
G |
H3C2 |
H3 clustered histone 2 |
decreases expression |
EXP |
Berberine results in decreased expression of H3C2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,031,589...26,032,099
Ensembl chr 6:26,031,589...26,032,099
|
|
G |
H3C4 |
H3 clustered histone 4 |
decreases expression |
EXP |
Berberine results in decreased expression of H3C4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,196,784...26,199,293
Ensembl chr 6:26,195,164...26,197,286
|
|
G |
H3C7 |
H3 clustered histone 7 |
decreases expression |
EXP |
Berberine results in decreased expression of H3C7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,250,142...26,250,635
Ensembl chr 6:26,250,142...26,250,635
|
|
G |
H3C8 |
H3 clustered histone 8 |
decreases expression |
EXP |
Berberine results in decreased expression of H3C8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,270,918...26,271,413
Ensembl chr 6:26,270,918...26,271,413
|
|
G |
H4C14 |
H4 clustered histone 14 |
decreases expression |
EXP |
Berberine results in decreased expression of H4C14 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:149,832,657...149,833,052
Ensembl chr 1:149,832,657...149,839,767
|
|
G |
H4C2 |
H4 clustered histone 2 |
decreases expression |
EXP |
Berberine results in decreased expression of H4C2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,026,896...26,027,283
Ensembl chr 6:26,025,802...26,027,283
|
|
G |
H4C3 |
H4 clustered histone 3 |
decreases expression |
EXP |
Berberine results in decreased expression of H4C3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,103,933...26,104,337
Ensembl chr 6:26,103,933...26,104,337
|
|
G |
H4C8 |
H4 clustered histone 8 |
decreases expression |
EXP |
Berberine results in decreased expression of H4C8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:26,285,126...26,285,534
Ensembl chr 6:26,277,609...26,285,638
|
|
G |
H4C9 |
H4 clustered histone 9 |
decreases expression |
EXP |
Berberine results in decreased expression of H4C9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:27,139,282...27,139,678
Ensembl chr 6:27,139,282...27,140,640
|
|
G |
HAT1 |
histone acetyltransferase 1 |
increases expression |
EXP |
Berberine results in increased expression of HAT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:171,922,461...171,983,686
Ensembl chr 2:171,922,448...171,983,686
|
|
G |
HDAC2 |
histone deacetylase 2 |
decreases expression |
EXP |
Berberine results in decreased expression of HDAC2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:113,933,028...113,971,148
Ensembl chr 6:113,933,028...114,011,308
|
|
G |
HDAC5 |
histone deacetylase 5 |
increases expression |
EXP |
Berberine results in increased expression of HDAC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,076,753...44,123,641
Ensembl chr17:44,076,746...44,123,702
|
|
G |
HDAC8 |
histone deacetylase 8 |
decreases expression |
EXP |
Berberine results in decreased expression of HDAC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:72,329,516...72,572,843
Ensembl chr X:72,329,516...72,573,101
|
|
G |
HDAC9 |
histone deacetylase 9 |
decreases expression increases expression |
EXP |
Berberine results in decreased expression of HDAC9 mRNA Berberine results in increased expression of HDAC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:18,086,825...19,002,416
Ensembl chr 7:18,086,949...19,002,416
|
|
G |
HGF |
hepatocyte growth factor |
multiple interactions increases expression |
ISO EXP |
Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein |
CTD |
PMID:29408570 |
|
NCBI chr 7:81,699,010...81,770,047
Ensembl chr 7:81,699,010...81,770,438
|
|
G |
HMGB1 |
high mobility group box 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein] |
CTD |
PMID:38705399 |
|
NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
Berberine results in increased expression of HMOX1 protein Berberine results in increased expression of HMOX1 mRNA; Berberine results in increased expression of HMOX1 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of HMOX1 protein] Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein] |
CTD |
PMID:23954465 PMID:35121005 PMID:37511356 PMID:37839514 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNF4A |
hepatocyte nuclear factor 4 alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein] |
CTD |
PMID:18563319 PMID:25455889 |
|
NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,699...44,432,845
|
|
G |
IDH3A |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
EXP |
Berberine results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr15:78,149,362...78,171,945
Ensembl chr15:78,131,498...78,171,945
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
ISO |
Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Berberine results in increased expression of IGF1R protein |
CTD |
PMID:23954465 |
|
NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
|
|
G |
IGF2BP3 |
insulin like growth factor 2 mRNA binding protein 3 |
multiple interactions decreases expression |
EXP ISO |
[Chloroquine co-treated with Berberine] results in decreased expression of IGF2BP3 protein; Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]; Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein] Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein] |
CTD |
PMID:36822301 |
|
NCBI chr 7:23,310,209...23,470,491
Ensembl chr 7:23,310,209...23,470,491
|
|
G |
IL10 |
interleukin 10 |
multiple interactions increases expression |
ISO |
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA Berberine results in increased expression of IL10 mRNA |
CTD |
PMID:21867779 PMID:30138605 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] |
CTD |
PMID:16391493 PMID:29170048 PMID:30138605 PMID:35121005 PMID:35691465 PMID:37839514 PMID:38705399 More...
|
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2 |
interleukin 2 |
increases expression |
ISO |
Berberine results in increased expression of IL2 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
IL23A |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein] |
CTD |
PMID:30240693 |
|
NCBI chr12:56,338,884...56,340,410
Ensembl chr12:56,334,174...56,340,410
|
|
G |
IL4 |
interleukin 4 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL6 protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]] |
CTD |
PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 PMID:34427876 PMID:35121005 PMID:35691465 PMID:37839514 PMID:38705399 More...
|
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INS |
insulin |
multiple interactions |
ISO |
[Berberine co-treated with Streptozocin] results in increased secretion of INS protein |
CTD |
PMID:15066220 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
|
|
G |
ITGA1 |
integrin subunit alpha 1 |
increases expression |
EXP |
Berberine results in increased expression of ITGA1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 5:52,787,916...52,959,209
Ensembl chr 5:52,787,916...52,959,209
|
|
G |
ITGB4 |
integrin subunit beta 4 |
increases expression |
EXP |
berberine increases expression of ITGB4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr17:75,721,459...75,757,818
Ensembl chr17:75,721,328...75,757,818
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects localization multiple interactions |
ISO |
Berberine affects the localization of JUN protein arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein] |
CTD |
PMID:18294404 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
ISO |
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KDM1A |
lysine demethylase 1A |
increases expression |
EXP |
Berberine results in increased expression of KDM1A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:23,019,468...23,083,689
Ensembl chr 1:23,019,443...23,083,689
|
|
G |
KDM4A |
lysine demethylase 4A |
increases expression |
EXP |
Berberine results in increased expression of KDM4A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:43,650,149...43,705,518
Ensembl chr 1:43,650,149...43,705,518
|
|
G |
KDM5B |
lysine demethylase 5B |
increases expression |
EXP |
Berberine results in increased expression of KDM5B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:202,724,495...202,808,421
Ensembl chr 1:202,724,495...202,808,487
|
|
G |
KDM6A |
lysine demethylase 6A |
increases expression |
EXP |
Berberine results in increased expression of KDM6A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:44,873,188...45,112,779
Ensembl chr X:44,873,188...45,112,779
|
|
G |
KDM6B |
lysine demethylase 6B |
increases expression |
EXP |
Berberine results in increased expression of KDM6B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:7,834,217...7,854,796
Ensembl chr17:7,834,217...7,854,796
|
|
G |
KMT5A |
lysine methyltransferase 5A |
increases expression |
EXP |
Berberine results in increased expression of KMT5A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:123,384,132...123,409,353
Ensembl chr12:123,384,132...123,409,353
|
|
G |
KPNA4 |
karyopherin subunit alpha 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]] |
CTD |
PMID:34427876 |
|
NCBI chr 3:160,495,007...160,565,571
Ensembl chr 3:160,495,007...160,565,571
|
|
G |
LDLR |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] |
CTD |
PMID:18640378 PMID:20564506 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LINC00943 |
long intergenic non-protein coding RNA 943 |
multiple interactions |
EXP |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of LINC00943 mRNA]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] |
CTD |
PMID:34427876 |
|
NCBI chr12:126,737,007...126,746,256
Ensembl chr12:126,723,412...126,749,027
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions increases localization |
EXP ISO |
[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine results in increased localization of MAP1LC3B protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of MAP1LC3B mRNA] |
CTD |
PMID:35439518 PMID:36070022 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAP3K5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 6:136,557,046...136,793,091
Ensembl chr 6:136,557,046...136,793,097
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:18294404 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO |
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA] |
CTD |
PMID:18294404 PMID:20462044 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36070022 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPT |
microtubule associated protein tau |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334
|
|
G |
MCM2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 3:127,598,411...127,622,436
Ensembl chr 3:127,598,223...127,622,436
|
|
G |
MIR142 |
microRNA 142 |
multiple interactions |
EXP |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of MIR142 mRNA]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] |
CTD |
PMID:34427876 |
|
NCBI chr17:58,331,232...58,331,318
Ensembl chr17:58,331,232...58,331,318
|
|
G |
MIR19A |
microRNA 19a |
decreases expression |
EXP |
Berberine results in decreased expression of MIR19A mRNA |
CTD |
PMID:29687521 |
|
NCBI chr13:91,350,891...91,350,972
Ensembl chr13:91,350,891...91,350,972
|
|
G |
MIR21 |
microRNA 21 |
decreases expression |
EXP |
berberine decreases expression of MIR21 RNA in colon epithelial cell |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr17:59,841,266...59,841,337
Ensembl chr17:59,841,266...59,841,337
|
|
G |
MIR92A1 |
microRNA 92a-1 |
decreases expression |
EXP |
Berberine results in decreased expression of MIR92A1 mRNA |
CTD |
PMID:29687521 |
|
NCBI chr13:91,351,314...91,351,391
Ensembl chr13:91,351,314...91,351,391
|
|
G |
MMP13 |
matrix metallopeptidase 13 |
increases expression |
EXP |
Berberine results in increased expression of MMP13 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr11:102,942,995...102,955,732
Ensembl chr11:102,942,995...102,955,732
|
|
G |
MMP14 |
matrix metallopeptidase 14 |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein] |
CTD |
PMID:18294404 |
|
NCBI chr14:22,836,585...22,847,758
Ensembl chr14:22,836,560...22,849,041
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] |
CTD |
PMID:18294404 PMID:33325633 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions decreases activity |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] |
CTD |
PMID:21963898 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MT-CO1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of COX1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:5,904...7,445
Ensembl chr MT:5,904...7,445
|
|
G |
MT-ND1 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of ND1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:3,307...4,262
Ensembl chr MT:3,307...4,262
|
|
G |
MT-ND2 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of ND2 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:4,470...5,511
Ensembl chr MT:4,470...5,511
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR mRNA]; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR protein] |
CTD |
PMID:35439518 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MTTP |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein] |
CTD |
PMID:25455889 |
|
NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects localization |
ISO |
arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein] |
CTD |
PMID:18294404 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NAMPT |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
EXP |
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein] |
CTD |
PMID:26712469 |
|
NCBI chr 7:106,248,298...106,285,888
Ensembl chr 7:106,248,298...106,285,966
|
|
G |
NCF1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein] |
CTD |
PMID:36070022 |
|
NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315
|
|
G |
NCF2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr 1:183,555,562...183,601,849
Ensembl chr 1:183,554,461...183,590,905
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions increases activity |
EXP ISO |
Berberine results in increased expression of NFE2L2 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of NFE2L2 protein] Berberine results in increased activity of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23523906 PMID:23954465 PMID:30818834 PMID:35121005 PMID:37839514 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]] |
CTD |
PMID:21963898 PMID:34427876 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
NGF |
nerve growth factor |
multiple interactions |
EXP |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23954465 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA] Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein] |
CTD |
PMID:35121005 PMID:38705399 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:21095217 PMID:23523906 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Berberine reverses reaction [Carbontetrachloride decreases Nqo1 mRNA in liver] Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA] |
CTD RGD |
PMID:35121005 PMID:31432116 |
RGD:25823187 |
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
increases localization |
EXP |
Berberine increases localization of NR1H3 protein in macrophage nucleus |
RGD |
PMID:20506155 |
RGD:401827279 |
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity multiple interactions |
EXP |
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21524698 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity |
EXP |
Berberine results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
NSD2 |
nuclear receptor binding SET domain protein 2 |
decreases expression |
EXP |
Berberine results in decreased expression of NSD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:1,871,393...1,982,192
Ensembl chr 4:1,871,393...1,982,207
|
|
G |
ODC1 |
ornithine decarboxylase 1 |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein] |
CTD |
PMID:18294404 |
|
NCBI chr 2:10,439,968...10,448,327
Ensembl chr 2:10,439,968...10,448,327
|
|
G |
OMD |
osteomodulin |
increases expression |
EXP |
Berberine results in increased expression of OMD mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 9:92,412,380...92,424,471
Ensembl chr 9:92,412,380...92,424,471
|
|
G |
P2RX7 |
purinergic receptor P2X 7 |
multiple interactions |
EXP |
Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:21320518 |
|
NCBI chr12:121,132,876...121,188,032
Ensembl chr12:121,132,819...121,188,032
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
EXP |
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein] |
CTD |
PMID:16505103 PMID:26712469 PMID:36070022 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PDCD4 |
programmed cell death 4 |
increases expression |
EXP |
Berberine increases expression of PDCD4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr10:110,871,928...110,900,006
Ensembl chr10:110,871,795...110,900,006
|
|
G |
PDK4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Berberine results in increased expression of PDK4 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARA protein] |
CTD |
PMID:18338635 PMID:25455889 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARD |
peroxisome proliferator activated receptor delta |
increases activity multiple interactions increases expression |
ISO |
Berberine results in increased activity of PPARD protein Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARD protein] Berberine results in increased expression of PPARD mRNA; Berberine results in increased expression of PPARD protein |
CTD |
PMID:18338635 PMID:37511356 |
|
NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases expression increases response to substance increases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in decreased expression of PPARG protein] Berberine results in decreased expression of PPARG mRNA; Berberine results in decreased expression of PPARG protein PPARG mRNA results in increased susceptibility to Berberine 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] Berberine results in increased expression of PPARG mRNA |
CTD |
PMID:18338635 PMID:20564506 PMID:26478571 PMID:29408570 PMID:37511356 PMID:37839514 More...
|
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PRG4 |
proteoglycan 4 |
decreases expression |
EXP |
Berberine results in decreased expression of PRG4 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:186,296,273...186,314,567
Ensembl chr 1:186,296,279...186,314,567
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
ISO |
Berberine results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:28298333 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
G |
PRKCA |
protein kinase C alpha |
multiple interactions |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein |
CTD |
PMID:18294404 |
|
NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743
|
|
G |
PRKCE |
protein kinase C epsilon |
multiple interactions decreases activity |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein |
CTD |
PMID:18294404 |
|
NCBI chr 2:45,651,279...46,187,990
Ensembl chr 2:45,651,345...46,187,990
|
|
G |
PRMT1 |
protein arginine methyltransferase 1 |
decreases expression |
EXP |
Berberine results in decreased expression of PRMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:49,676,153...49,688,447
Ensembl chr19:49,675,786...49,689,029
|
|
G |
PRMT2 |
protein arginine methyltransferase 2 |
increases expression |
EXP |
Berberine results in increased expression of PRMT2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr21:46,635,674...46,665,124
Ensembl chr21:46,635,595...46,665,685
|
|
G |
PRMT5 |
protein arginine methyltransferase 5 |
increases expression |
EXP |
Berberine results in increased expression of PRMT5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:22,920,529...22,929,376
Ensembl chr14:22,920,525...22,929,408
|
|
G |
PRMT6 |
protein arginine methyltransferase 6 |
increases expression |
EXP |
Berberine results in increased expression of PRMT6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:107,056,674...107,059,294
Ensembl chr 1:107,056,674...107,067,636
|
|
G |
PRMT7 |
protein arginine methyltransferase 7 |
increases expression |
EXP |
Berberine results in increased expression of PRMT7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr16:68,311,019...68,360,870
Ensembl chr16:68,310,951...68,360,852
|
|
G |
PRMT8 |
protein arginine methyltransferase 8 |
increases expression |
EXP |
Berberine results in increased expression of PRMT8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:3,381,349...3,593,973
Ensembl chr12:3,381,349...3,593,973
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein |
CTD |
PMID:29408570 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] |
CTD |
PMID:21095217 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA] |
CTD |
PMID:38705399 |
|
NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450
|
|
G |
RAC2 |
Rac family small GTPase 2 |
multiple interactions |
EXP |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein |
CTD |
PMID:36070022 |
|
NCBI chr22:37,225,270...37,244,269
Ensembl chr22:37,225,270...37,259,594
|
|
G |
RBP4 |
retinol binding protein 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr10:93,591,694...93,601,744
Ensembl chr10:93,591,687...93,601,744
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]] |
CTD |
PMID:23523906 PMID:34427876 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RLN1 |
relaxin 1 |
affects binding increases expression multiple interactions |
ISO |
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA |
CTD |
PMID:22363579 |
|
NCBI chr 9:5,334,930...5,340,916
Ensembl chr 9:5,334,930...5,339,876
|
|
G |
RPS6 |
ribosomal protein S6 |
decreases phosphorylation |
EXP |
Berberine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
EXP |
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26478571 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
SETD1B |
SET domain containing 1B, histone lysine methyltransferase |
increases expression |
EXP |
Berberine results in increased expression of SETD1B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:121,790,155...121,832,656
Ensembl chr12:121,804,009...121,832,656
|
|
G |
SETD2 |
SET domain containing 2, histone lysine methyltransferase |
increases expression |
EXP |
Berberine results in increased expression of SETD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:47,016,436...47,164,840
Ensembl chr 3:47,016,428...47,164,113
|
|
G |
SETD3 |
SET domain containing 3, actin N3(tau)-histidine methyltransferase |
increases expression |
EXP |
Berberine results in increased expression of SETD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:99,397,748...99,486,458
Ensembl chr14:99,397,748...99,480,889
|
|
G |
SETD5 |
SET domain containing 5 |
increases expression |
EXP |
Berberine results in increased expression of SETD5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:9,397,615...9,478,154
Ensembl chr 3:9,397,615...9,479,240
|
|
G |
SETD6 |
SET domain containing 6, protein lysine methyltransferase |
increases expression |
EXP |
Berberine results in increased expression of SETD6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr16:58,515,479...58,523,842
Ensembl chr16:58,515,479...58,523,842
|
|
G |
SETD7 |
SET domain containing 7, histone lysine methyltransferase |
increases expression |
EXP |
Berberine results in increased expression of SETD7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:139,492,974...139,556,219
Ensembl chr 4:139,495,941...139,606,699
|
|
G |
SETDB1 |
SET domain bifurcated histone lysine methyltransferase 1 |
increases expression |
EXP |
Berberine results in increased expression of SETDB1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:150,926,263...150,964,737
Ensembl chr 1:150,926,263...150,964,744
|
|
G |
SETDB2 |
SET domain bifurcated histone lysine methyltransferase 2 |
increases expression |
EXP |
Berberine results in increased expression of SETDB2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:49,444,274...49,495,003
Ensembl chr13:49,444,274...49,495,003
|
|
G |
SI |
sucrase-isomaltase |
decreases expression multiple interactions |
EXP ISO |
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 3:164,978,898...165,090,232
Ensembl chr 3:164,978,898...165,078,496
|
|
G |
SIRT1 |
sirtuin 1 |
decreases expression multiple interactions |
EXP ISO |
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein] |
CTD |
PMID:26712469 PMID:35121005 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SIRT2 |
sirtuin 2 |
multiple interactions |
EXP |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:26712469 |
|
NCBI chr19:38,878,555...38,899,618
Ensembl chr19:38,878,555...38,899,862
|
|
G |
SIRT3 |
sirtuin 3 |
multiple interactions increases expression decreases expression |
EXP |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 PMID:27311644 |
|
NCBI chr11:215,030...236,931
Ensembl chr11:215,030...236,931
|
|
G |
SLC27A5 |
solute carrier family 27 member 5 |
decreases expression |
EXP |
Berberine results in decreased expression of SLC27A5 mRNA |
CTD |
PMID:28038998 |
|
NCBI chr19:58,498,333...58,511,992
Ensembl chr19:58,479,512...58,512,413
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SLC6A19 |
solute carrier family 6 member 19 |
multiple interactions |
ISO |
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein] |
CTD |
PMID:21073932 |
|
NCBI chr 5:1,201,595...1,225,111
Ensembl chr 5:1,201,595...1,225,111
|
|
G |
SMYD3 |
SET and MYND domain containing 3 |
affects expression |
EXP |
Berberine affects the expression of SMYD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:245,749,347...246,507,279
Ensembl chr 1:245,749,342...246,507,312
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 mRNA]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 protein] |
CTD |
PMID:37839514 |
|
NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of SOD1 protein] |
CTD |
PMID:21095217 PMID:22775417 PMID:35439518 PMID:37839514 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [acetamiprid results in decreased expression of SOD2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:22775417 PMID:24751971 PMID:33460233 PMID:37350525 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
decreases expression |
EXP |
Berberine results in decreased expression of SOX9 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
SP7 |
Sp7 transcription factor |
increases expression |
EXP |
Berberine results in increased expression of SP7 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr12:53,326,575...53,344,793
Ensembl chr12:53,326,575...53,345,315
|
|
G |
SPARC |
secreted protein acidic and cysteine rich |
increases expression |
EXP |
Berberine results in increased expression of SPARC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 5:151,661,096...151,686,915
Ensembl chr 5:151,661,096...151,686,975
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
EXP |
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SQSTM1 |
sequestosome 1 |
increases expression multiple interactions |
EXP ISO |
Berberine results in increased expression of SQSTM1 protein [Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein |
CTD |
PMID:36070022 PMID:38705399 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of STAT3 mRNA] |
CTD |
PMID:35121005 PMID:37839514 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
TERT |
telomerase reverse transcriptase |
decreases activity |
EXP |
Berberine results in decreased activity of TERT protein |
CTD |
PMID:25265580 |
|
NCBI chr 5:1,253,167...1,295,068
Ensembl chr 5:1,253,147...1,295,068
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of TGFB1 mRNA] Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] |
CTD |
PMID:17973934 PMID:23523906 PMID:30138605 PMID:37839514 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein] |
CTD |
PMID:21963898 PMID:30240693 PMID:35121005 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
EXP ISO |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Dietary Fats results in increased secretion of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of TNF protein] |
CTD |
PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 PMID:25600690 PMID:28533128 PMID:29170048 PMID:30240693 PMID:34427876 PMID:35121005 PMID:35691465 PMID:37511356 PMID:37839514 PMID:38705399 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TOP1 |
DNA topoisomerase I |
decreases activity |
EXP |
Berberine results in decreased activity of TOP1 protein |
CTD |
PMID:23747414 |
|
NCBI chr20:41,028,822...41,124,487
Ensembl chr20:41,028,822...41,124,487
|
|
G |
TOP2A |
DNA topoisomerase II alpha |
multiple interactions affects response to substance |
EXP |
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine |
CTD |
PMID:23747414 |
|
NCBI chr17:40,388,525...40,417,896
Ensembl chr17:40,388,525...40,417,896
|
|
G |
TP53 |
tumor protein p53 |
increases expression multiple interactions |
EXP |
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein |
CTD |
PMID:20656010 PMID:26712469 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TRAF1 |
TNF receptor associated factor 1 |
increases expression |
EXP |
Berberine results in increased expression of TRAF1 protein |
CTD |
PMID:20656010 |
|
NCBI chr 9:120,902,393...120,929,171
Ensembl chr 9:120,902,393...120,929,173
|
|
G |
TRAF2 |
TNF receptor associated factor 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 9:136,881,958...136,926,607
Ensembl chr 9:136,881,912...136,926,607
|
|
G |
TRIM21 |
tripartite motif containing 21 |
multiple interactions |
EXP |
Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein] |
CTD |
PMID:36822301 |
|
NCBI chr11:4,384,897...4,393,702
Ensembl chr11:4,384,897...4,393,702
|
|
G |
TSTD1 |
thiosulfate sulfurtransferase like domain containing 1 |
increases expression |
EXP |
Berberine results in increased expression of TSTD1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:161,037,631...161,038,964
Ensembl chr 1:161,037,631...161,038,977
|
|
G |
UBE2A |
ubiquitin conjugating enzyme E2 A |
decreases expression |
EXP |
Berberine results in decreased expression of UBE2A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:119,574,563...119,584,423
Ensembl chr X:119,474,802...119,591,083
|
|
G |
UBE2B |
ubiquitin conjugating enzyme E2 B |
decreases expression |
EXP |
Berberine results in decreased expression of UBE2B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:134,371,569...134,392,108
Ensembl chr 5:134,371,184...134,392,108
|
|
G |
UCP2 |
uncoupling protein 2 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA] Berberine results in increased expression of UCP2 mRNA |
CTD |
PMID:28533128 PMID:37511356 |
|
NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,061...73,982,843
|
|
G |
VEGFA |
vascular endothelial growth factor A |
decreases expression |
EXP |
Berberine results in decreased expression of VEGFA protein |
CTD |
PMID:33325633 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VEGFC |
vascular endothelial growth factor C |
increases expression |
EXP |
Berberine results in increased expression of VEGFC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 4:176,683,538...176,792,922
Ensembl chr 4:176,683,538...176,792,922
|
|
|
G |
FKBP1B |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
dofetilide inhibits the reaction [Isoproterenol results in decreased expression of FKBP1B mRNA]; dofetilide inhibits the reaction [Isoproterenol results in decreased expression of FKBP1B protein] |
CTD |
PMID:20723002 |
|
NCBI chr 2:24,033,206...24,063,681
Ensembl chr 2:24,049,701...24,063,681
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity affects binding |
EXP |
[Terfenadine co-treated with dofetilide] binds to and results in decreased activity of KCNH2 protein; Acids inhibits the reaction [dofetilide results in decreased activity of KCNH2 protein]; dofetilide analog inhibits the reaction [Astemizole binds to KCNH2 protein]; dofetilide analog inhibits the reaction [dofetilide binds to KCNH2 protein]; dofetilide binds to and results in decreased activity of KCNH2 protein; dofetilide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; dofetilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; Hydrogen Peroxide inhibits the reaction [dofetilide results in decreased activity of KCNH2 protein mutant form]; naringenin promotes the reaction [dofetilide results in decreased activity of KCNH2 protein]; Potassium affects the reaction [dofetilide analog inhibits the reaction [dofetilide binds to KCNH2 protein]]; Potassium inhibits the reaction [dofetilide results in decreased activity of KCNH2 protein]; Potassium promotes the reaction [dofetilide binds to KCNH2 protein] |
CTD |
PMID:9395068 PMID:10828461 PMID:15272206 PMID:15821840 PMID:15961988 PMID:16960444 PMID:17042915 PMID:18057881 PMID:18701618 PMID:20071423 PMID:21158687 PMID:24052561 PMID:24200993 PMID:24830940 PMID:30561737 More...
|
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
NCF2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
dofetilide inhibits the reaction [Isoproterenol results in increased expression of NCF2 mRNA]; dofetilide inhibits the reaction [Isoproterenol results in increased expression of NCF2 protein] |
CTD |
PMID:20723002 |
|
NCBI chr 1:183,555,562...183,601,849
Ensembl chr 1:183,554,461...183,590,905
|
|
G |
PRKCE |
protein kinase C epsilon |
multiple interactions |
ISO |
dofetilide inhibits the reaction [Isoproterenol results in increased expression of PRKCE mRNA]; dofetilide inhibits the reaction [Isoproterenol results in increased expression of PRKCE protein] |
CTD |
PMID:20723002 |
|
NCBI chr 2:45,651,279...46,187,990
Ensembl chr 2:45,651,345...46,187,990
|
|
|
G |
CACNA1C |
calcium voltage-gated channel subunit alpha1 C |
affects activity |
EXP |
ezogabine affects the activity of CACNA1C protein |
CTD |
PMID:28641963 |
|
NCBI chr12:1,970,780...2,697,950
Ensembl chr12:1,970,772...2,697,950
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
ezogabine inhibits the reaction [Sarin results in increased expression of IL1B protein] |
CTD |
PMID:32209366 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
ezogabine inhibits the reaction [Sarin results in increased expression of IL6 protein] |
CTD |
PMID:32209366 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
EXP |
ezogabine affects the activity of KCNH2 protein |
CTD |
PMID:28641963 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KCNQ2 |
potassium voltage-gated channel subfamily Q member 2 |
multiple interactions affects activity |
ISO EXP |
ezogabine affects the reaction [[Potassium results in increased activity of KCNQ2 protein] which results in increased import of Thallium] ezogabine affects the activity of KCNQ2 protein |
CTD |
PMID:15634793 PMID:26627826 |
|
NCBI chr20:63,400,208...63,472,655
Ensembl chr20:63,400,208...63,472,677
|
|
G |
KCNQ3 |
potassium voltage-gated channel subfamily Q member 3 |
decreases response to substance affects activity |
EXP |
KCNQ3 protein mutant form results in decreased susceptibility to ezogabine ezogabine affects the activity of KCNQ3 protein |
CTD |
PMID:26627826 |
|
NCBI chr 8:132,120,861...132,481,095
Ensembl chr 8:132,120,861...132,481,095
|
|
G |
KCNQ4 |
potassium voltage-gated channel subfamily Q member 4 |
multiple interactions increases activity |
EXP |
[ezogabine results in increased activity of KCNQ4 protein] which results in increased export of Rubidium; [ezogabine results in increased activity of KCNQ4 protein] which results in increased import of Thallium |
CTD |
PMID:16904708 PMID:21782781 |
|
NCBI chr 1:40,783,787...40,840,452
Ensembl chr 1:40,783,787...40,840,452
|
|
G |
SAE1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
EXP |
ezogabine results in decreased expression of SAE1 protein |
CTD |
PMID:34509475 |
|
NCBI chr19:47,130,835...47,210,636
Ensembl chr19:47,113,274...47,210,636
|
|
G |
SCN5A |
sodium voltage-gated channel alpha subunit 5 |
affects activity |
EXP |
ezogabine affects the activity of SCN5A protein |
CTD |
PMID:28641963 |
|
NCBI chr 3:38,548,062...38,649,687
Ensembl chr 3:38,548,057...38,649,743
|
|
G |
TSPO |
translocator protein |
multiple interactions |
ISO |
ezogabine inhibits the reaction [Sarin results in increased expression of TSPO protein] |
CTD |
PMID:32209366 |
|
NCBI chr22:43,151,559...43,163,242
Ensembl chr22:43,151,547...43,163,242
|
|
|
G |
ABCC9 |
ATP binding cassette subfamily C member 9 |
increases activity |
ISO |
Nicorandil results in increased activity of ABCC9 protein |
CTD |
PMID:22622455 |
|
NCBI chr12:21,797,389...21,941,426
Ensembl chr12:21,797,389...21,942,543
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] |
CTD |
PMID:22622455 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
ALB |
albumin |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in decreased expression of ALB protein] |
CTD |
PMID:33404076 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein] Nicorandil inhibits the reaction [Folic Acid results in increased expression of BAX protein] |
CTD |
PMID:31376360 PMID:33404076 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] |
CTD |
PMID:31376360 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in increased expression of CASP3 protein] |
CTD |
PMID:33404076 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] |
CTD |
PMID:31376360 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CTSD |
cathepsin D |
multiple interactions |
ISO |
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:11829124 PMID:14499179 |
|
NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573
|
|
G |
GAL |
galanin and GMAP prepropeptide |
multiple interactions |
ISO |
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:11829124 PMID:14499179 |
|
NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175
|
|
G |
GUSB |
glucuronidase beta |
multiple interactions |
ISO |
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:11829124 PMID:14499179 |
|
NCBI chr 7:65,960,684...65,982,213
Ensembl chr 7:65,960,684...65,982,215
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] |
CTD |
PMID:31376360 |
|
NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396
|
|
G |
HMOX1 |
heme oxygenase 1 |
decreases expression |
ISO |
Nicorandil results in decreased expression of HMOX1 protein |
CTD |
PMID:22622455 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] |
CTD |
PMID:31376360 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in increased expression of IL6 protein] |
CTD |
PMID:33404076 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] |
CTD |
PMID:31376360 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:31376360 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] |
CTD |
PMID:31376360 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in increased expression of NOS2 protein] |
CTD |
PMID:33404076 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Folic Acid results in decreased expression of NOS3 protein] |
CTD |
PMID:33404076 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
SOD2 |
superoxide dismutase 2 |
increases expression |
ISO |
Nicorandil results in increased expression of SOD2 protein |
CTD |
PMID:22622455 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] |
CTD |
PMID:31376360 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein] Nicorandil inhibits the reaction [Folic Acid results in increased expression of TNF protein] |
CTD |
PMID:31376360 PMID:33404076 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
XDH |
xanthine dehydrogenase |
multiple interactions decreases expression |
ISO |
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] Nicorandil results in decreased expression of XDH protein |
CTD |
PMID:22622455 |
|
NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]] |
CTD |
PMID:21413024 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
FLT1 |
fms related receptor tyrosine kinase 1 |
multiple interactions |
EXP |
NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]; paxilline inhibits the reaction [NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]] |
CTD |
PMID:25371888 |
|
NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145
|
|
G |
KCNMA1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions |
EXP |
NS 1619 binds to and results in increased activity of KCNMA1 protein; NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]] |
CTD |
PMID:21413024 |
|
NCBI chr10:76,869,602...77,637,808
Ensembl chr10:76,869,601...77,638,369
|
|
G |
KCNMB1 |
potassium calcium-activated channel subfamily M regulatory beta subunit 1 |
multiple interactions |
EXP |
NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]] |
CTD |
PMID:21413024 |
|
NCBI chr 5:170,374,671...170,389,367
Ensembl chr 5:170,374,671...170,389,634
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]] |
CTD |
PMID:12807996 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]] |
CTD |
PMID:12807996 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
FASN |
fatty acid synthase |
multiple interactions increases expression |
EXP |
[Bexarotene co-treated with paxilline] results in increased expression of FASN mRNA; [CD 3254 co-treated with paxilline] results in increased expression of FASN mRNA paxilline results in increased expression of FASN mRNA |
CTD |
PMID:32123961 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FLT1 |
fms related receptor tyrosine kinase 1 |
multiple interactions |
EXP |
paxilline inhibits the reaction [NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]] |
CTD |
PMID:25371888 |
|
NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145
|
|
G |
KCNMA1 |
potassium calcium-activated channel subfamily M alpha 1 |
affects response to substance |
ISO |
KCNMA1 protein affects the susceptibility to paxilline |
CTD |
PMID:22226998 |
|
NCBI chr10:76,869,602...77,637,808
Ensembl chr10:76,869,601...77,638,369
|
|
G |
MLXIPL |
MLX interacting protein like |
increases expression |
EXP |
paxilline results in increased expression of MLXIPL mRNA |
CTD |
PMID:32123961 |
|
NCBI chr 7:73,593,202...73,647,907
Ensembl chr 7:73,593,194...73,624,543
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
multiple interactions increases expression |
EXP |
[Bexarotene co-treated with paxilline] results in increased expression of NR0B2 mRNA; [CD 3254 co-treated with paxilline] results in increased expression of NR0B2 mRNA paxilline results in increased expression of NR0B2 mRNA |
CTD |
PMID:32123961 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
multiple interactions increases expression |
EXP |
[Bexarotene co-treated with paxilline] results in increased expression of NR1H3 mRNA; [CD 3254 co-treated with paxilline] results in increased expression of NR1H3 mRNA; NR1H3 protein promotes the reaction [paxilline results in increased abundance of Lipids] paxilline results in increased expression of NR1H3 mRNA |
CTD |
PMID:20079722 PMID:32123961 |
|
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NRIP1 |
nuclear receptor interacting protein 1 |
multiple interactions increases expression |
EXP |
[CD 3254 co-treated with paxilline] results in increased expression of NRIP1 mRNA paxilline results in increased expression of NRIP1 mRNA |
CTD |
PMID:32123961 |
|
NCBI chr21:14,961,235...15,065,936
Ensembl chr21:14,961,235...15,065,936
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions |
EXP |
paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]] |
CTD |
PMID:12807996 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
SCD |
stearoyl-CoA desaturase |
increases expression multiple interactions |
EXP |
paxilline results in increased expression of SCD mRNA [CD 3254 co-treated with paxilline] results in increased expression of SCD mRNA |
CTD |
PMID:32123961 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
increases expression multiple interactions |
EXP |
paxilline results in increased expression of SREBF1 mRNA [Bexarotene co-treated with paxilline] results in increased expression of SREBF1 mRNA; [CD 3254 co-treated with paxilline] results in increased expression of SREBF1 mRNA |
CTD |
PMID:32123961 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]] |
CTD |
PMID:12807996 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects transport increases transport affects binding affects response to substance decreases expression multiple interactions |
EXP ISO |
ABCB1 protein affects the transport of Quinidine ABCB1 protein results in increased transport of Quinidine Quinidine binds to ABCB1 protein ABCB1A protein affects the susceptibility to Quinidine Quinidine results in decreased expression of ABCB1 protein methoxyfenozide inhibits the reaction [ABCB1 protein results in increased transport of Quinidine]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to docetaxel]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; tebufenozide inhibits the reaction [ABCB1 protein results in increased transport of Quinidine] |
CTD |
PMID:15502009 PMID:15616150 PMID:20196146 PMID:23976943 PMID:26995013 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ACADM |
acyl-CoA dehydrogenase medium chain |
decreases expression |
ISO |
Quinidine results in decreased expression of ACADM mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
decreases expression |
EXP |
Quinidine results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ADRA1A |
adrenoceptor alpha 1A |
affects binding multiple interactions |
EXP |
Quinidine binds to ADRA1A protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr 8:26,748,150...26,867,379
Ensembl chr 8:26,748,150...26,867,278
|
|
G |
ADRA1B |
adrenoceptor alpha 1B |
affects binding multiple interactions |
EXP |
Quinidine binds to ADRA1B protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr 5:159,865,086...159,989,205
Ensembl chr 5:159,865,080...159,973,012
|
|
G |
ADRA1D |
adrenoceptor alpha 1D |
affects binding multiple interactions |
EXP |
Quinidine binds to ADRA1D protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr20:4,220,630...4,249,287
Ensembl chr20:4,220,630...4,249,287
|
|
G |
ALDOA |
aldolase, fructose-bisphosphate A |
increases expression |
ISO |
Quinidine results in increased expression of ALDOA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr16:30,064,279...30,070,420
Ensembl chr16:30,064,164...30,070,457
|
|
G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
EXP |
Quinidine results in increased expression of ASNS mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
|
|
G |
CAT |
catalase |
increases expression |
ISO |
Quinidine results in increased expression of CAT protein |
CTD |
PMID:12708743 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
Quinidine results in increased expression of CDKN1A protein |
CTD |
PMID:12243503 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
|
|
G |
CEACAM1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Quinidine results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr19:42,507,306...42,528,481
Ensembl chr19:42,507,304...42,561,234
|
|
G |
CYB5R3 |
cytochrome b5 reductase 3 |
decreases expression |
ISO |
Quinidine results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr22:42,617,840...42,649,392
Ensembl chr22:42,615,730...42,720,870
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions decreases activity |
EXP ISO |
Quinidine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Quinidine results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 PMID:18493746 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions decreases activity |
EXP |
Quinidine affects the reaction [CYP1A2 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Quinidine results in decreased activity of CYP1A2 protein |
CTD |
PMID:15916432 PMID:19053182 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2A7 |
cytochrome P450 family 2 subfamily A member 7 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr19:40,875,439...40,882,231
Ensembl chr19:40,875,439...40,882,752
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
multiple interactions decreases activity |
EXP ISO |
Quinidine affects the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Quinidine results in decreased activity of CYP2C6 protein |
CTD |
PMID:12814958 PMID:19053182 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2C29 protein |
CTD |
PMID:18420780 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2C9 protein |
CTD |
PMID:18420780 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene) |
increases metabolic processing decreases activity multiple interactions |
EXP ISO |
CYP2D6 protein results in increased metabolism of Quinidine Quinidine results in decreased activity of CYP2D6 protein [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride [Quinidine results in decreased activity of CYP2D6 protein] which affects the susceptibility to Oxycodone; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of 4-hydroxy-N-desmethyltamoxifen; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased hydroxylation of N-desmethyltamoxifen; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; Quinidine affects the reaction [CYP2D6 protein polymorphism affects the metabolism of dacomitinib]; Quinidine binds to and results in decreased activity of CYP2D6 protein; Quinidine inhibits the reaction [3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin results in increased metabolism of CYP2D6 protein]; Quinidine inhibits the reaction [[CYP2D6 protein results in increased metabolism of 7-methoxy-4-(aminomethyl)coumarin] which results in increased chemical synthesis of Coumarins]; Quinidine inhibits the reaction [CYP2D6 protein affects the metabolism of 1-(3-chlorophenyl)piperazine]; Quinidine inhibits the reaction [CYP2D6 protein results in increased chemical synthesis of Dextrorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased hydrolysis of bufuralol]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Atomoxetine Hydrochloride]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of auriculasin]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of bufuralol]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of tegaserod]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of YM 758]; Quinidine inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein] Quinidine results in decreased activity of CYP2D6 gene mutant form; Quinidine results in decreased activity of CYP2D6 protein |
CTD |
PMID:8819299 PMID:11377097 PMID:11560869 PMID:11673748 PMID:12464242 PMID:12467917 PMID:12569440 PMID:12814958 PMID:14652237 PMID:15155557 PMID:15306208 PMID:15860655 PMID:16035375 PMID:16595712 PMID:17702393 PMID:18238857 PMID:18420780 PMID:19230594 PMID:19328226 PMID:20345925 PMID:20590588 PMID:20669986 PMID:21277363 PMID:21336516 PMID:21915887 PMID:23850985 PMID:24167220 PMID:26599973 PMID:28119166 PMID:28887089 PMID:31515991 PMID:32198085 PMID:33253783 PMID:33438235 PMID:34431675 PMID:34936353 More...
|
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2E1 protein |
CTD |
PMID:18420780 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
affects metabolic processing multiple interactions |
EXP |
CYP3A4 protein affects the metabolism of Quinidine Quinidine inhibits the reaction [CYP3A4 protein results in increased metabolism of YM 758]; Quinidine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:2271712 PMID:15784650 PMID:19230594 PMID:19299527 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DEPP1 |
DEPP autophagy regulator 1 |
increases expression |
EXP |
Quinidine results in increased expression of DEPP1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr10:44,976,128...44,978,809
Ensembl chr10:44,970,981...44,978,809
|
|
G |
FABP1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Quinidine results in increased expression of FABP1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062
|
|
G |
FGA |
fibrinogen alpha chain |
increases expression |
ISO |
Quinidine results in increased expression of FGA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:154,583,126...154,590,742
Ensembl chr 4:154,583,126...154,590,742
|
|
G |
FGB |
fibrinogen beta chain |
increases expression |
ISO |
Quinidine results in increased expression of FGB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807
|
|
G |
GSTM1 |
glutathione S-transferase mu 1 |
decreases activity |
EXP |
Quinidine results in decreased activity of GSTM1 protein |
CTD |
PMID:11807801 |
|
NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
|
|
G |
GSTM3 |
glutathione S-transferase mu 3 |
decreases expression |
ISO |
Quinidine results in decreased expression of GSTM3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:109,733,937...109,741,038
Ensembl chr 1:109,733,932...109,741,038
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions decreases activity |
EXP |
Quinidine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid] Quinidine results in decreased activity of GSTP1 protein |
CTD |
PMID:11807801 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
HIBADH |
3-hydroxyisobutyrate dehydrogenase |
increases expression |
ISO |
Quinidine results in increased expression of HIBADH mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:27,525,442...27,662,883
Ensembl chr 7:27,525,442...27,662,883
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein] |
CTD |
PMID:17520698 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
INHBE |
inhibin subunit beta E |
increases expression |
EXP |
Quinidine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 |
|
NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280
|
|
G |
KCNH1 |
potassium voltage-gated channel subfamily H member 1 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein] |
CTD |
PMID:17520698 |
|
NCBI chr 1:210,678,314...211,134,148
Ensembl chr 1:210,676,823...211,134,165
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity affects activity affects binding affects localization affects response to substance decreases response to substance |
EXP |
[Quinidine results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; Acids inhibits the reaction [Quinidine results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [Quinidine results in decreased activity of KCNH2 protein]; Potassium inhibits the reaction [Quinidine results in decreased activity of KCNH2 protein]; Quinidine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Quinidine promotes the reaction [naringenin results in decreased activity of KCNH2 protein] Quinidine affects the activity of KCNH2 protein Quinidine binds to KCNH2 protein Quinidine affects the localization of KCNH2 protein mutant form KCNH2 gene SNP affects the susceptibility to Quinidine KCNH2 gene mutant form results in decreased susceptibility to Quinidine |
CTD |
PMID:11741928 PMID:12695533 PMID:15671647 PMID:15673388 PMID:15821840 PMID:16960444 PMID:17042915 PMID:18057881 PMID:18701618 PMID:18724381 PMID:19583963 PMID:21158687 PMID:21362439 PMID:22020101 PMID:24052561 PMID:28551711 More...
|
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KCNK1 |
potassium two pore domain channel subfamily K member 1 |
multiple interactions |
ISO |
Quinidine affects the reaction [KCNK1 protein results in increased transport of Potassium]; Quinidine inhibits the reaction [KCNK1 protein results in increased transport of Sodium] |
CTD |
PMID:16847696 |
|
NCBI chr 1:233,614,106...233,672,514
Ensembl chr 1:233,614,106...233,672,514
|
|
G |
KCNK18 |
potassium two pore domain channel subfamily K member 18 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr10:117,197,489...117,210,299
Ensembl chr10:117,197,489...117,210,299
|
|
G |
KCNK9 |
potassium two pore domain channel subfamily K member 9 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [KCNK9 protein results in increased transport of Potassium] |
CTD |
PMID:10734076 |
|
NCBI chr 8:139,600,838...139,703,123
Ensembl chr 8:139,600,838...139,704,109
|
|
G |
LBP |
lipopolysaccharide binding protein |
increases expression |
ISO |
Quinidine results in increased expression of LBP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013
|
|
G |
LIPC |
lipase C, hepatic type |
decreases expression |
ISO |
Quinidine results in decreased expression of LIPC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Quinidine results in decreased expression of MYC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NUPR1 |
nuclear protein 1, transcriptional regulator |
increases expression |
EXP |
Quinidine results in increased expression of NUPR1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr16:28,532,708...28,538,974
Ensembl chr16:28,532,708...28,539,008
|
|
G |
OTC |
ornithine transcarbamylase |
decreases expression |
ISO |
Quinidine results in decreased expression of OTC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:38,327,684...38,422,928
Ensembl chr X:38,327,598...38,422,908
|
|
G |
PKLR |
pyruvate kinase L/R |
decreases expression |
ISO |
Quinidine results in decreased expression of PKLR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438
|
|
G |
PTMA |
prothymosin alpha |
decreases expression |
ISO |
Quinidine results in decreased expression of PTMA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:231,708,525...231,713,551
Ensembl chr 2:231,706,895...231,713,551
|
|
G |
S100A9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Quinidine results in increased expression of S100A9 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
|
|
G |
SCN5A |
sodium voltage-gated channel alpha subunit 5 |
affects response to substance |
ISO |
SCN5A gene mutant form affects the susceptibility to Quinidine |
CTD |
PMID:17805561 |
|
NCBI chr 3:38,548,062...38,649,687
Ensembl chr 3:38,548,057...38,649,743
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO EXP |
[Quinidine analog results in decreased activity of SLC22A1 protein] which results in decreased import of Phenylephrine; [Quinidine analog results in decreased activity of SLC22A1 protein] which results in decreased import of Synephrine Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of Monocrotaline]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of Quercetin]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of retrorsine] |
CTD |
PMID:16141367 PMID:21140131 PMID:23831208 PMID:24799337 PMID:24947867 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:16141367 PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLC22A3 |
solute carrier family 22 member 3 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16141367 |
|
NCBI chr 6:160,348,378...160,452,577
Ensembl chr 6:160,348,378...160,452,577
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
decreases expression |
EXP |
Quinidine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007
|
|
G |
SLC47A1 |
solute carrier family 47 member 1 |
decreases activity multiple interactions |
EXP |
Quinidine results in decreased activity of SLC47A1 protein Quinidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16928787 PMID:22419765 |
|
NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034
|
|
G |
SLC47A2 |
solute carrier family 47 member 2 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979
|
|
G |
TAGLN |
transgelin |
decreases expression |
EXP |
Quinidine results in decreased expression of TAGLN mRNA |
CTD |
PMID:17567588 |
|
NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Quinidine results in increased expression of TIMP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Quinidine results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TNFRSF1A |
TNF receptor superfamily member 1A |
decreases expression |
ISO |
Quinidine results in decreased expression of TNFRSF1A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114
|
|
G |
TNFRSF8 |
TNF receptor superfamily member 8 |
decreases expression |
EXP |
Quinidine results in decreased expression of TNFRSF8 protein |
CTD |
PMID:12441127 |
|
NCBI chr 1:12,063,303...12,144,207
Ensembl chr 1:12,063,303...12,144,207
|
|
G |
TP53 |
tumor protein p53 |
decreases expression |
ISO |
Quinidine results in decreased expression of TP53 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
increases response to substance |
ISO |
Tolazamide results in increased susceptibility to INS1 protein |
CTD |
PMID:6337899 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
decreases activity multiple interactions |
EXP |
Tolbutamide results in decreased activity of ABCB1 protein Tolbutamide inhibits the reaction [ABCB1 protein results in increased uptake of quinidinium] |
CTD |
PMID:32305507 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
EXP |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein]; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein] |
CTD |
PMID:9568693 PMID:18025464 PMID:22209866 |
|
NCBI chr11:17,392,498...17,476,845
Ensembl chr11:17,392,498...17,476,894
|
|
G |
ALB |
albumin |
affects binding |
EXP |
Tolbutamide binds to ALB protein |
CTD |
PMID:19596536 PMID:20435530 PMID:20956006 PMID:20974553 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
CCND1 |
cyclin D1 |
increases expression |
ISO |
Tolbutamide results in increased expression of CCND1 protein |
CTD |
PMID:16718685 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND3 |
cyclin D3 |
increases expression |
ISO |
Tolbutamide results in increased expression of CCND3 protein |
CTD |
PMID:16718685 |
|
NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein] |
CTD |
PMID:16718685 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression |
ISO |
Tolbutamide results in increased expression of CDKN1B protein |
CTD |
PMID:16718685 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CYP2C18 |
cytochrome P450 family 2 subfamily C member 18 |
increases metabolic processing |
EXP |
CYP2C18 results in increased metabolism of Tolbutamide |
CTD |
PMID:15301741 |
|
NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
increases metabolic processing increases hydroxylation multiple interactions |
EXP |
CYP2C19 protein results in increased metabolism of Tolbutamide CYP2C19 protein results in increased hydroxylation of Tolbutamide [CYP2C19 protein results in increased hydroxylation of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:18511451 PMID:30500380 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C23P |
cytochrome P450 family 2 subfamily C member 23, pseudogene |
multiple interactions increases metabolic processing |
ISO |
[CYP2C23 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr10:100,105,754...100,140,151
Ensembl chr10:100,105,754...100,140,151
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
increases hydroxylation |
EXP |
CYP2C8 protein results in increased hydroxylation of Tolbutamide |
CTD |
PMID:15843491 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions increases metabolic processing increases hydroxylation increases chemical synthesis affects metabolic processing affects hydroxylation decreases hydroxylation decreases metabolic processing increases hydrolysis |
EXP ISO |
[CYP2C9 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide; Acetone promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; acetonitrile promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; CYP2C9 gene mutant form inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; CYP2C9 protein binds to and affects the metabolism of Tolbutamide; Fenitrothion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; Malathion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; phenthoate inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; pranlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; profenofos inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased hydrolysis of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; Ticlopidine inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; Tolbutamide inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; zafirlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide] CYP2C65 protein results in increased metabolism of Tolbutamide [CYP2C65 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide CYP2C9 protein results in increased chemical synthesis of Tolbutamide metabolite CYP2C9 gene polymorphism affects the metabolism of Tolbutamide; CYP2C9 gene SNP affects the metabolism of Tolbutamide; CYP2C9 protein affects the metabolism of Tolbutamide CYP2C9 protein affects the hydroxylation of Tolbutamide CYP2C9 gene SNP results in decreased hydroxylation of Tolbutamide CYP2C9 gene polymorphism results in decreased metabolism of Tolbutamide |
CTD |
PMID:2025243 PMID:9110362 PMID:9170147 PMID:9522436 PMID:10208645 PMID:10611138 PMID:11377097 PMID:11875364 PMID:12426520 PMID:12433797 PMID:12464242 PMID:12467917 PMID:15045499 PMID:15155557 PMID:15327588 PMID:15370959 PMID:15626586 PMID:15843491 PMID:15856409 PMID:16081671 PMID:16124035 PMID:17267297 PMID:17565714 PMID:17702393 PMID:19082874 PMID:19715737 PMID:21915887 PMID:22634058 PMID:23850985 PMID:25994031 PMID:26255664 PMID:26763401 PMID:30503582 PMID:32198085 More...
|
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
GCG |
glucagon |
increases secretion |
ISO |
Tolbutamide results in increased secretion of GCG protein |
CTD |
PMID:15919803 |
|
NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404
|
|
G |
GJA1 |
gap junction protein alpha 1 |
multiple interactions increases expression |
ISO |
GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] Tolbutamide results in increased expression of GJA1 protein |
CTD |
PMID:11741589 PMID:16718685 |
|
NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727
|
|
G |
HK1 |
hexokinase 1 |
increases expression |
ISO |
Tolbutamide results in increased expression of HK1 protein |
CTD |
PMID:11835228 |
|
NCBI chr10:69,270,000...69,401,882
Ensembl chr10:69,269,984...69,401,884
|
|
G |
INS |
insulin |
multiple interactions increases secretion |
EXP |
ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein] |
CTD |
PMID:9032110 PMID:9568693 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
affects secretion multiple interactions |
ISO |
Tolbutamide affects the secretion of INS1 protein [Tolbutamide co-treated with FR900359] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Tolbutamide inhibits the reaction [arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [dimethylarsinous acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [methylarsonite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide promotes the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:9366569 PMID:31332465 PMID:37217659 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
KCNJ11 |
potassium inwardly rectifying channel subfamily J member 11 |
multiple interactions decreases activity |
EXP |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein] Tolbutamide results in decreased activity of KCNJ11 protein |
CTD |
PMID:18025464 PMID:22209866 |
|
NCBI chr11:17,385,248...17,389,346
Ensembl chr11:17,365,172...17,389,331
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Tolbutamide results in decreased expression of MKI67 protein |
CTD |
PMID:16718685 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
PDCD4 |
programmed cell death 4 |
decreases expression increases expression |
EXP |
Tolbutamide results in decreased expression of PDCD4 mRNA Tolbutamide results in increased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr10:110,871,928...110,900,006
Ensembl chr10:110,871,795...110,900,006
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
Tolbutamide results in decreased phosphorylation of RB1 protein |
CTD |
PMID:16718685 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
Tolbutamide results in increased expression of SLC2A1 mRNA; Tolbutamide results in increased expression of SLC2A1 protein |
CTD |
PMID:2682625 PMID:11835228 |
|
NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Tolbutamide results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
decreases expression |
EXP |
Tolbutamide results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
|
|
G |
TP53 |
tumor protein p53 |
increases expression |
ISO |
Tolbutamide results in increased expression of TP53 mRNA |
CTD |
PMID:16426753 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TPD52 |
tumor protein D52 |
decreases expression increases expression |
EXP |
Tolbutamide results in decreased expression of TPD52 mRNA Tolbutamide results in increased expression of TPD52 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 8:80,031,082...80,171,564
Ensembl chr 8:80,034,745...80,231,232
|
|
G |
UGDH |
UDP-glucose 6-dehydrogenase |
decreases expression |
ISO |
Tolbutamide results in decreased expression of UGDH protein |
CTD |
PMID:4270849 |
|
NCBI chr 4:39,498,755...39,527,439
Ensembl chr 4:39,498,755...39,528,311
|
|
|
G |
AGT |
angiotensinogen |
increases expression |
ISO |
Torsemide results in increased expression of AGT protein modified form |
CTD |
PMID:18154949 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
CYP11B2 |
cytochrome P450 family 11 subfamily B member 2 |
affects expression |
ISO |
Torsemide affects the expression of CYP11B2 protein |
CTD |
PMID:18001696 |
|
NCBI chr 8:142,910,559...142,917,843
Ensembl chr 8:142,910,559...142,917,843
|
|
G |
CYP2C18 |
cytochrome P450 family 2 subfamily C member 18 |
affects metabolic processing |
ISO |
CYP2C11 protein affects the metabolism of Torsemide |
CTD |
PMID:15890479 |
|
NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
multiple interactions increases metabolic processing |
EXP |
Torsemide inhibits the reaction [Amiodarone results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Fluoxetine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Nortriptyline results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Phenelzine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein] CYP2C8 protein results in increased metabolism of Torsemide |
CTD |
PMID:15304522 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
increases hydroxylation increases metabolic processing |
EXP |
CYP2C9 protein results in increased hydroxylation of Torsemide CYP2C9 protein results in increased metabolism of Torsemide |
CTD |
PMID:9110362 PMID:19082874 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
NPPA |
natriuretic peptide A |
decreases expression |
ISO |
Torsemide results in decreased expression of NPPA protein |
CTD |
PMID:18154949 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
NR3C2 |
nuclear receptor subfamily 3 group C member 2 |
multiple interactions |
ISO |
Torsemide inhibits the reaction [Aldosterone binds to NR3C2 protein] |
CTD |
PMID:7954537 |
|
NCBI chr 4:148,078,764...148,445,508
Ensembl chr 4:148,078,762...148,444,698
|
|
G |
REN |
renin |
increases expression |
ISO |
Torsemide results in increased expression of REN protein |
CTD |
PMID:7954537 |
|
NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324
|
|
G |
SLC12A2 |
solute carrier family 12 member 2 |
multiple interactions decreases activity |
EXP |
Torsemide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium] Torsemide results in decreased activity of SLC12A2 protein |
CTD |
PMID:29959396 |
|
NCBI chr 5:128,083,766...128,189,677
Ensembl chr 5:128,083,766...128,189,677
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
affects expression decreases expression |
ISO |
Torsemide affects the expression of TGFB1 protein Torsemide results in decreased expression of TGFB1 protein |
CTD |
PMID:18001696 PMID:18154949 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects export |
EXP |
ABCC2 protein affects the export of polydatin |
CTD |
PMID:15686436 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of MYH7 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of TGFB1 protein] |
CTD |
PMID:25488910 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AHR |
aryl hydrocarbon receptor |
decreases localization multiple interactions |
EXP |
polydatin results in decreased localization of AHR protein polydatin promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] |
CTD |
PMID:21756928 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
EXP |
polydatin results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 1:150,809,713...150,876,599
Ensembl chr 1:150,809,713...150,876,708
|
|
G |
ATG5 |
autophagy related 5 |
multiple interactions |
EXP |
polydatin inhibits the reaction [Rotenone results in decreased expression of ATG5 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO EXP |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA] polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein] |
CTD |
PMID:27481074 PMID:28980048 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein] polydatin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein] |
CTD |
PMID:27481074 PMID:29130132 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases secretion decreases expression |
EXP |
polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA] polydatin results in decreased secretion of CCL2 protein polydatin results in decreased expression of CCL2 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA] |
CTD |
PMID:27481074 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND2 |
cyclin D2 |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA] |
CTD |
PMID:27481074 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
multiple interactions decreases secretion decreases expression |
EXP |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA] polydatin results in decreased secretion of CXCL10 protein polydatin results in decreased expression of CXCL10 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions increases secretion decreases expression |
EXP |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL8 mRNA]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] polydatin results in increased secretion of CXCL8 protein polydatin results in decreased expression of CXCL8 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein] |
CTD |
PMID:25488910 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression |
EXP |
polydatin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21967610 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions |
ISO |
ESR2 gene mutant form inhibits the reaction [polydatin results in increased expression of SOD2 protein] |
CTD |
PMID:24361291 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
decreases activity |
EXP |
polydatin results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GLI1 |
GLI family zinc finger 1 |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein] |
CTD |
PMID:27481074 |
|
NCBI chr12:57,459,785...57,472,268
Ensembl chr12:57,459,785...57,472,268
|
|
G |
HLCS |
holocarboxylase synthetase |
decreases activity |
EXP |
polydatin results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr21:36,748,625...36,990,211
Ensembl chr21:36,748,626...36,990,236
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA] |
CTD |
PMID:29130132 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
ISO |
polydatin inhibits the reaction [OVAL protein results in increased secretion of IL4 protein] |
CTD |
PMID:23840142 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL6 |
interleukin 6 |
multiple interactions decreases expression |
EXP |
polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] polydatin results in decreased expression of IL6 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
multiple interactions |
EXP ISO |
polydatin inhibits the reaction [Hydrogen Peroxide results in increased expression of KEAP1 protein] polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
|
|
G |
LCT |
lactase |
increases hydrolysis |
ISO |
LCT protein results in increased hydrolysis of polydatin analog |
CTD |
PMID:17009167 |
|
NCBI chr 2:135,787,850...135,837,184
Ensembl chr 2:135,787,850...135,837,184
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
EXP |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK1 protein] polydatin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:28980048 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation decreases phosphorylation |
EXP |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK3 protein] polydatin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:28980048 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK7 |
mitogen-activated protein kinase 7 |
multiple interactions increases phosphorylation |
EXP |
XMD 8-92 inhibits the reaction [polydatin results in increased phosphorylation of MAPK7 protein] |
CTD |
PMID:28980048 |
|
NCBI chr17:19,377,750...19,383,544
Ensembl chr17:19,377,721...19,383,544
|
|
G |
MFN2 |
mitofusin 2 |
multiple interactions |
EXP |
polydatin inhibits the reaction [Rotenone results in increased expression of MFN2 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 1:11,980,444...12,013,508
Ensembl chr 1:11,980,181...12,015,211
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
polydatin inhibits the reaction [Rotenone results in increased phosphorylation of MTOR protein] |
CTD |
PMID:31926197 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MYH7 |
myosin heavy chain 7 |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of MYH7 mRNA] |
CTD |
PMID:25488910 |
|
NCBI chr14:23,412,740...23,435,660
Ensembl chr14:23,412,740...23,435,660
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP ISO |
[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein; NFE2L2 protein affects the reaction [[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]] polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein] |
CTD |
PMID:31705858 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NOX4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein] |
CTD |
PMID:25488910 |
|
NCBI chr11:89,324,353...89,589,557
Ensembl chr11:89,324,353...89,498,187
|
|
G |
NPPA |
natriuretic peptide A |
multiple interactions |
ISO |
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased expression of NPPA protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [Phenylephrine results in increased expression of NPPA protein] |
CTD |
PMID:25449040 PMID:25488910 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP ISO |
NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]]; polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein] polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
ORAI1 |
ORAI calcium release-activated calcium modulator 1 |
affects response to substance |
ISO |
ORAI1 protein affects the susceptibility to polydatin |
CTD |
PMID:22959927 |
|
NCBI chr12:121,626,530...121,643,109
Ensembl chr12:121,626,509...121,643,218
|
|
G |
PARK7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
[PRKN protein affects the susceptibility to polydatin] which results in increased expression of PARK7 protein; polydatin inhibits the reaction [Rotenone results in increased expression of PARK7 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 1:7,961,711...7,985,505
Ensembl chr 1:7,954,291...7,985,505
|
|
G |
PDE5A |
phosphodiesterase 5A |
decreases activity |
EXP |
polydatin results in decreased activity of PDE5A protein |
CTD |
PMID:15769121 |
|
NCBI chr 4:119,494,403...119,628,804
Ensembl chr 4:119,494,397...119,628,804
|
|
G |
PPARGC1B |
PPARG coactivator 1 beta |
decreases expression |
EXP |
polydatin results in decreased expression of PPARGC1B protein |
CTD |
PMID:31926197 |
|
NCBI chr 5:149,730,310...149,857,959
Ensembl chr 5:149,730,298...149,855,022
|
|
G |
PPP1R12A |
protein phosphatase 1 regulatory subunit 12A |
multiple interactions |
ISO |
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased phosphorylation of PPP1R12A protein]; polydatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr12:79,773,563...79,935,460
Ensembl chr12:79,773,563...79,935,460
|
|
G |
PRKN |
parkin RBR E3 ubiquitin protein ligase |
affects response to substance multiple interactions |
EXP |
PRKN protein affects the susceptibility to polydatin [PRKN protein affects the susceptibility to polydatin] which results in increased expression of PARK7 protein |
CTD |
PMID:31926197 |
|
NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
ISO |
polydatin results in decreased activity of PTGS1 protein |
CTD |
PMID:11962253 |
|
NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases activity |
EXP ISO |
[polydatin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA polydatin results in decreased activity of PTGS2 protein |
CTD |
PMID:11962253 PMID:21756928 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA] |
CTD |
PMID:21756928 PMID:29130132 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RHOA |
ras homolog family member A |
multiple interactions |
ISO |
polydatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein] |
CTD |
PMID:25449040 |
|
NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998
|
|
G |
SHH |
sonic hedgehog signaling molecule |
multiple interactions |
ISO |
polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased secretion of SHH protein] |
CTD |
PMID:27481074 |
|
NCBI chr 7:155,799,980...155,812,463
Ensembl chr 7:155,799,980...155,812,463
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
EXP |
polydatin inhibits the reaction [Rotenone results in decreased expression of SIRT1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLC22A12 |
solute carrier family 22 member 12 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein] |
CTD |
PMID:22865646 |
|
NCBI chr11:64,591,220...64,602,344
Ensembl chr11:64,590,641...64,602,353
|
|
G |
SLC22A4 |
solute carrier family 22 member 4 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 5:132,294,394...132,344,190
Ensembl chr 5:132,294,394...132,344,190
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein] |
CTD |
PMID:22865646 |
|
NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967
|
|
G |
SLC2A9 |
solute carrier family 2 member 9 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 4:9,771,025...10,040,270
Ensembl chr 4:9,771,153...10,054,936
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
affects uptake |
EXP |
SLC5A1 protein affects the uptake of polydatin |
CTD |
PMID:15686436 |
|
NCBI chr22:32,043,261...32,113,029
Ensembl chr22:32,043,261...32,113,029
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions increases expression |
EXP ISO |
polydatin results in increased expression of and results in increased activity of SOD2 protein polydatin results in increased expression of SOD2 protein ESR2 gene mutant form inhibits the reaction [polydatin results in increased expression of SOD2 protein]; fulvestrant inhibits the reaction [polydatin results in increased expression of SOD2 protein] |
CTD |
PMID:24361291 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
EXP |
polydatin promotes the reaction [Rotenone results in decreased expression of SQSTM1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
TGFA |
transforming growth factor alpha |
multiple interactions |
EXP |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; [polydatin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of TGFB1 protein] |
CTD |
PMID:25488910 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA] polydatin results in decreased expression of TNF mRNA |
CTD |
PMID:21756928 PMID:29130132 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] |
CTD |
PMID:29130132 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TSHR |
thyroid stimulating hormone receptor |
multiple interactions |
ISO |
polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein]; polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein]; polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr14:80,955,621...81,146,306
Ensembl chr14:80,954,989...81,146,306
|
|
G |
TUG1 |
taurine up-regulated 1 |
decreases expression |
EXP |
polydatin results in decreased expression of TUG1 mRNA |
CTD |
PMID:30974157 |
|
NCBI chr22:30,969,265...30,979,395
Ensembl chr22:30,969,245...30,979,395
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
increases hydrolysis |
EXP |
UGT1A1 protein results in increased hydrolysis of polydatin metabolite |
CTD |
PMID:17009167 |
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
|
|
G |
ULK1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
EXP |
polydatin inhibits the reaction [Rotenone results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr12:131,894,622...131,923,150
Ensembl chr12:131,894,622...131,923,150
|
|
G |
UMOD |
uromodulin |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of and results in decreased secretion of UMOD protein] |
CTD |
PMID:22865646 |
|
NCBI chr16:20,333,051...20,356,301
Ensembl chr16:20,333,051...20,356,301
|
|